Author: Jesse Landry

Some companies raise money. Others make a point. SynthBee just made a statement, and it was said calmly, deliberately, and with the kind of confidence that does not need a megaphone. $100M, closed clean, from a single strategic investor, Crosspoint Capital Partners. No valuation chest beating. No hype parade. Just conviction, timing, and architecture that actually understands the stakes when AI leaves the lab and walks into regulated, mission critical reality. Rony Abovitz has been here before, which is exactly why this moment lands differently. Founded in 2022 in Fort Lauderdale, SynthBee was not born out of trend chasing or…

There is a moment in every market where the noise drops out and you can hear the machinery underneath. The gears, the friction, the parts nobody on CNBC wants to explain because it does not fit in a chyron. Crypto is there again. Not the speculative circus, not the meme economy, but the hard reality that value moving at internet speed attracts predators at the same velocity. TRM Labs was built for that moment, and the market just confirmed it with $70M Series C at a $1B valuation. Esteban Castaño and Rahul Raina did not wander into this problem by…

Money does not usually make noise. It moves quietly, through conference rooms and wire transfers, nodding at spreadsheets like they told a good joke. But every once in a while, capital clears its throat and says something worth hearing. Overland AI just did that with a $100M Series B plus venture debt round, and if you work anywhere near autonomy, defense, or the uncomfortable future where machines have to go where humans should not, you probably felt the bassline. Founded in 2022 and built out of the University of Washington Robot Learning Lab, Overland AI came from a simple and…

Evergreen Select used to be called Omeat, which tells you everything about where this story starts and why it matters. In a market addicted to shiny slogans and lab-coated optimism, this company took a breath, changed the name on the door, and doubled down on something far more dangerous than hype: execution. The kind that survives market cycles, regulatory scrutiny, and dinner table conversations where people still ask uncomfortable questions about their food. The headline is clean. Evergreen Select closed a $6M Series A extension, pushing total capital north of $55M+. S2G Investments leaned back in, BOLD Capital Partners stayed…

SonoVascular, Inc. just raised $6M in Series A first close, and no, this is not one of those polite golf claps the market gives out of habit. This one has resonance. Literal and financial. Harbright Ventures led the round, and Robert Ross stepped onto the board, which tells you this is not tourist capital. This is conviction money that reads the room before the room knows it is being read. Daniel Estay, CEO, did not stumble into this company. Daniel Estay went hunting for it. In 2017, while most people were skimming headlines, Daniel Estay was reading a vascular medicine…

Every sales deck says speed matters. Every founder nods. Then the buyer lands on your site at 11:47 PM, curious, qualified, and gone by midnight because no one was there to talk back. That gap between intent and interaction is where deals go to die quietly. Naoma AI exists in that gap, staring at it like a problem that got way too comfortable being ignored, then deciding to do something impolite about it. Naoma AI just closed a $440K pre-seed round led by ULTRA.VC, with Sparkle Ventures and a lineup of angel investors stepping in early. That number is modest…

In trucking, truth has always moved slower than the freight. Clipboards, phone calls, gut checks, and a whole lot of trust in a system that moves trillions of dollars while running on vibes and partial data. That gap between what is happening and what is provable is where fraud, theft, and inefficiency quietly feast. GenLogs did not come from logistics folklore or legacy software. It came from people who spent careers chasing ground truth when the stakes were life, death, and national security. Ryan Joyce (CEO), Joe Sherman (CTO), and Blake Balch (Chief of Strategy and Partnerships) took intelligence community…

Cambridge, Massachusetts has seen its share of smart people doing smart things, but Synthpop, Inc. feels less like a lab experiment and more like a late night studio session where the beat finally locks. Founded in 2023 by Elad Ferber and Jan Jannink, PhD, this is healthcare AI built by operators who have lived the paperwork pain and decided boredom was no longer an acceptable outcome. The headline landed February 4, 2026. Synthpop raised a $15 million Series A, pushing total funding to $23 million, led by Ansa Capital with Defy.vc, Peterson Ventures, Storm Ventures, and Bruce Broussard stepping in.…

When the skies clear, you either take off or you taxi in circles pretending the weather is complicated. CAVU Consumer Partners just punched through the clouds and did what disciplined conviction looks like at scale, closing Fund V at $325M. Oversubscribed. Target cleared by $50M. More than 90% of existing limited partners came back for seconds. That is not momentum. That is trust earned the long way, with reps, receipts, and a memory longer than the last cycle. CAVU has always been honest about the metaphor. Ceiling and Visibility Unlimited is not about vibes, it is about clarity. Brett Thomas…

Imbed Biosciences has been quietly doing what the best companies do. No noise, no cosplay entrepreneurship, just real science, real clinicians, real scars earned in the field. Founded in 2010 out of the University of Wisconsin Madison by a crew of physicians and scientists who actually touch wounds for a living, Imbed did not chase hype. It chased outcomes. That matters in a $22B wound care market where 8M Americans are living with chronic wounds and the system spends $148B a year trying to clean up what half baked solutions leave behind. The latest chapter lands with a strategic investment…